“The primary completion is projected for 2027; however, the study will read out when the target number of progression events are accrued.”

In context

“isorder. We expect to initiate several more phase II and phase III trials in 2026, exploring how brenepatide may be able to treat other conditions, including a phase three trial for major depressive disorder, testing if brenepatide can prevent relapse of disease. In Alzheimer's disease, we continue to look forward to the results from Trailblazer ALS3, our study of donanemab in people with normal cognition but a positive blood test for Alzheimer's disease. This trial screened volunteers with a blood test for p-tau and randomized participants to a nine-month course of treatment with donanemab. By moving earlier in disease, even prior to individuals having any objective symptoms of Alzheimer's disease, the goal is to reduce the risks of them ever developing any impairment due to Alzheimer's. The primary completion is projected for 2027; however, the study will read out when the target number of progression events are accrued. Moving to cardiometabolic health, we had another busy quarter. We were excited to announce positive top-line results from the INTEIN VANTAIN trial, evaluating orforglipron for weight maintenance. This unique phase three trial was designed to answer a common question from doctors and patients: Can people successfully maintain weight loss achieved on the maximum tolerated dose of injectable incretins by switching to an oral GLP-1 therapy? Participants in ATTAINMANTAIN previously on injectable semaglutide or tirzepatide then switched to orforglipron or placebo. As shown on slide 16, orforglipron helped people maintain weight loss that they had achieved on injectable therapies, and the study met all primary and secondary endpoints. People who switched from semaglutide to orforglipron maintain”